Epidemiology

Unlocking Growth Opportunities: Explore the Neurovascular Thrombectomy Devices Market for Strategic Planning and Investment Insights - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Health, Cardiology, Medical Devices, Neurovascular bundle, Grand Rapids Medical Mile, Epidemiology, Segment, Investment, Strategic planning, SWOT, Region, Country, Stryker Corporation, COVID-19, Internet, Medtronic, CMO, Market access, Procedure, Health care, Pharmaceutical industry, Retail, Heavy equipment, Video game, Risk management, Czech Republic, Others

The model discusses in detail the impact of COVID-19 on Neurovascular Thrombectomy Devices market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Neurovascular Thrombectomy Devices market for the year 2020 and beyond.
  • Neurovascular thrombectomy devices are used for the removal of a blood clot in the neurovascular vessels during an acute ischemic stroke.
  • Key Inclusions of the market model are:
    Currently marketed Neurovascular Thrombectomy Devices and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Annualized total Neurovascular Thrombectomy Devices market revenue by segment and market outlooks from 2015-2033.

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

Retrieved on: 
Monday, November 13, 2023
Research, Women, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Science, Oncology, Obstetrics and gynaecology, Woman, Epidemiology, Pathology, Gynaecology, Tubing (recreation), Verastem Oncology, Patient, Peritoneum, Neoplasm, Diagnosis, Cancer, Ovarian cancer, Partnership, Mental health, Obstetrics, Ovary, Education, Medical imaging, MD

LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years.

Key Points: 
  • LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years.
  • For many patients, LGSOC symptoms and treatment side effects have a long-lasting impact on physical and mental health.
  • “LGSOC has only recently been classified as a separate disease as compared to the more common high-grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation, and outcomes.
  • “In addition to our work to help deliver new innovative treatment options for LGSOC, we aim to raise awareness of this distinct and different form of ovarian cancer that is under- researched and often misunderstood.

Rapid Technological Advancements Drive Growth in the Global POC Analyzers Market, Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Health Technology, Health, Medical Devices, Forecast, LIBOR market model, POC, Epidemiology, Investment, Patient, ASP, Strategic planning, SWOT, Region, Country, COVID-19, Internet, CMO, Market access, Physician, Segment, SWOT analysis, Immunochemistry, Retail, Medical device, Pharmaceutical industry, Health care, Marketing, Management, Risk management

The model discusses in detail the impact of COVID-19 on POC Analyzers market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on POC Analyzers market for the year 2020 and beyond.
  • POC Analyzers market is segmented into POC PCR Systems, POC Immunochemistry Analyzers and POC Hand-held Analyzers.
  • Key Inclusions of the market model are:
    Currently marketed POC Analyzers and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Track device sales in the global and country-specific POC Analyzers market from 2015-2033.

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Retrieved on: 
Friday, November 10, 2023
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Medicine, AstraZeneca, Biostatistics, Therapy, University of Queensland, University, Research, Bristol Myers Squibb, OrbiMed, MBBS, Terra Venture Partners, MD, Drug discovery, Growth, Synthetic biology, Cytosol, GSK plc, Enzyme, Drug development, Pharmaceutical industry, Epidemiology

NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.

Key Points: 
  • NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.
  • Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
  • Most recently, Tony held the position of Chief Executive Officer at Goldfinch Bio and is Chair of the Board of Directors at Outrun Therapeutics.
  • Tony brings extensive and broad expertise to NanoSyrinx, particularly in drug discovery and early clinical development.

The ACSR Democratizes Access To Pathology Data With Proscia, Advancing Breakthroughs For HIV Cancer Patients

Retrieved on: 
Tuesday, December 12, 2023
Research, SAN, Pathology, National Cancer Institute, UCSF, Patient, Informatics, ACSR, HIV, Melanoma, Person, Cancer, Software, AIDS, Bangladesh Technical Education Board, News, Medical imaging, Biostatistics, PLWH, Epidemiology

SAN FRANCISCO and PHILADELPHIA, Dec. 12, 2023 /PRNewswire-PRWeb/ -- The AIDS and Cancer Specimen Resource (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) established in 1994 and funded by the National Institutes of Health, National Cancer Institute, is using software from Proscia®, a leading provider of digital and computational pathology solutions, to encourage scientific exploration and discovery in cancer in PLWH. Concentriq® for Research has enabled the ACSR to provide near real-time access to pathology data to investigators around the world.

Key Points: 
  • Concentriq® for Research has enabled the ACSR to provide near real-time access to pathology data to investigators around the world.
  • As digital pathology shifts the standard from microscope to high-resolution images, the ACSR recognized an opportunity to improve access to its data and drive further breakthroughs by adopting the technology.
  • Since selecting Concentriq for Research, the ACSR has reduced the time it takes to provide investigators with pathology data from days to hours.
  • "It enables breakthrough research with its pathology data and has meaningfully improved access to this critical source of insight with our platform.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

Syra Health to Expand its Innovative Solutions to Federal Government Agencies

Retrieved on: 
Thursday, December 7, 2023
Health, Research, Organization, CLAS, Federation, Epidemiology, Race (human categorization), REACH, CDC, Medicare, Community health, Government, Nursing

CARMEL, Ind., Dec. 7, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced that it is expanding its reach beyond state and local government agencies to now include supplying its products, services, and solutions to the federal government.

Key Points: 
  • CARMEL, Ind., Dec. 7, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced that it is expanding its reach beyond state and local government agencies to now include supplying its products, services, and solutions to the federal government.
  • "Expanding our business at the federal level is a natural next step for Syra Health," said Dr. Deepika Vuppalanchi, CEO, Syra Health.
  • Syra Health currently has 13 active contracts across 12 states nationwide, supplying state and local governments with clinical staffing, mental and behavioral health solutions, and population health services.
  • "We have a strong foundation of health and medical services, solutions, and clinical staffing that allow us to expand into the federal market," said Sandeep Allam, Executive Chairman and President, Syra Health.

New Study Shows Point-of-care Genetics May Improve Uptake, Reduce Racial Disparities

Retrieved on: 
Thursday, December 7, 2023
POC, Associate professor, Entrepreneurship, Cancer, Genetic counseling, Risk, Patient, Trust, Genetic testing, Biomarker, Risk assessment, Public health, Doctor of Philosophy, Pharmaceutical industry, MD, Epidemiology

CHICAGO, Dec. 7, 2023 /PRNewswire-PRWeb/ -- To identify more equitable models for cancer genetic testing, a team of researchers from Boston University School of Public Health and CancerIQ examined racial/ethnic disparities along the continuum of cancer genetic service delivery. The goal of the study was to identify specific areas of patient attrition along clinical workflows to improve genetic testing processes and reduce racial disparities in cancer genetic testing. Results were published in the peer-reviewed Cancer, Epidemiology, Biomarkers and Prevention.

Key Points: 
  • The goal of the study was to identify specific areas of patient attrition along clinical workflows to improve genetic testing processes and reduce racial disparities in cancer genetic testing.
  • "Now that we have more information about what is driving disparities in genomic testing and how to solve for it, we need to put it into clinical practice."
  • Fewer than 1 in 5 high-risk individuals receive genetic testing, and most of those patients have not discussed testing with a healthcare provider.
  • This study demonstrates providers equipped to discuss and act on the results of cancer risk assessment with patients at the point-of-care may improve genetic counseling rates and eliminate disparities in testing uptake among racial/ethnic minority groups.

NFID Calls for 2024 Awards Nominations Honoring Public Health Heroes

Retrieved on: 
Wednesday, November 29, 2023
Health equity, Policy, Epidemiology, Organization, Infection, Award, Vaccine, NFID, Carter Center, MPH, Diagnosis, Democracy, Maxwell Finland, Public, Pharmaceutical industry, MD

BETHESDA, Md., Nov. 29, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) is calling for nominations for the 2024 annual awards to honor public health heroes who have made significant and lasting contributions to global public health through scientific achievement, philanthropy, and policy work.

Key Points: 
  • BETHESDA, Md., Nov. 29, 2023 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) is calling for nominations for the 2024 annual awards to honor public health heroes who have made significant and lasting contributions to global public health through scientific achievement, philanthropy, and policy work.
  • NFID is now accepting nominations for:
    Named for former President and the late Mrs. Carter, the award honors individuals whose outstanding humanitarian efforts and achievements have contributed significantly to improving global public health through domestic and/or international activities.
  • Nominees must be living at the time of nomination and selected recipients must agree to attend the NFID Awards Gala in Washington, DC in September 2024 to receive the award.
  • Current members of the NFID Board of Directors are not eligible for nomination and self-nominations will not be accepted.

The Harvard Medical School Master of Science in Media, Medicine, and Health program presents Portraying HIV & AIDS in the Media: How Far Have We Come?

Retrieved on: 
Tuesday, November 28, 2023
PITCH, Yale University, Television, Global health, Master of Science, Epidemiology, Social medicine, HIV/AIDS, Organization, NYPD, CSI, Hospital, Treatment Action Group, LOST, Division, GOOD, EMPIRE, GLEE, Partner, Photography, Human, Right Alliance (Belarus), HIV, MPH, Harvard Medical School, Curriculum, SCANDAL, ANARCHY, AIDS, International Emmy Awards, Doctor of Philosophy, HOUSE, Up, Up and Away, GMHC, Cone Health Women's Hospital, Management, Pharmaceutical industry, Science, Medicine, MD, Health, Brigham

This event is sponsored by the Harvard Medical School Master of Science in Media, Medicine, and Health program in the Harvard Medical School Department of Global Health and Social Medicine.

Key Points: 
  • This event is sponsored by the Harvard Medical School Master of Science in Media, Medicine, and Health program in the Harvard Medical School Department of Global Health and Social Medicine.
  • The Master of Science in Media, Medicine, and Health is the only master's degree program in the United States to offer evidence-based, multidisciplinary storytelling and an arts-driven curriculum focusing on health interventions.
  • In the Department of Global Health and Social Medicine, she directs the Master of Medical Sciences in Global Health Delivery program.
  • We invite you to learn more about these programs in the Harvard Medical School Department of Global Health and Social Medicine.